Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday, November 30th, BidAskClub reports.
Several other analysts have also weighed in on CRSP. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Goldman Sachs Group boosted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Finally, ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average price target of $71.38.
Shares of NASDAQ CRSP traded down $0.18 during midday trading on Friday, hitting $67.88. The company had a trading volume of 924,070 shares, compared to its average volume of 715,699. Crispr Therapeutics has a twelve month low of $22.36 and a twelve month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.75 billion, a price-to-earnings ratio of -19.73 and a beta of 3.30. The business has a 50-day simple moving average of $63.17 and a two-hundred day simple moving average of $49.95.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. On average, equities analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last 90 days. Insiders own 21.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth $4,366,000. Orbimed Advisors LLC acquired a new stake in Crispr Therapeutics during the third quarter worth about $21,167,000. Granahan Investment Management Inc. MA increased its stake in Crispr Therapeutics by 8.3% during the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after acquiring an additional 2,655 shares during the last quarter. Barclays PLC raised its holdings in shares of Crispr Therapeutics by 42.7% in the 3rd quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after purchasing an additional 4,151 shares during the period. Finally, Stifel Financial Corp raised its holdings in shares of Crispr Therapeutics by 18.0% in the 3rd quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after purchasing an additional 1,491 shares during the period. 49.82% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.